Therapeutic cancer vaccines revamping: technology advancements and pitfalls

Cancer vaccines (CVs) represent a long-sought therapeutic and prophylactic immunotherapy strategy to obtain antigen (Ag)-specific T-cell responses and potentially achieve long-term clinical benefit. However, historically, most CV clinical trials have resulted in disappointing outcomes, despite promi...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortes, J., Romero, P., Mittendorf, E.A., Disis, M.L., Curigliano, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420263/
https://www.ncbi.nlm.nih.gov/pubmed/34500046
http://dx.doi.org/10.1016/j.annonc.2021.08.2153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420263/
https://www.ncbi.nlm.nih.gov/pubmed/34500046
http://dx.doi.org/10.1016/j.annonc.2021.08.2153

Ejemplares similares